SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCVS Group Regulatory News (CVSG)

Share Price Information for CVS Group (CVSG)

Share Price is delayed by 15 minutes
Get Live Data
1,215.00    -16.00 (-1.30%)
Bid:
1,215.00
Ask:
1,248.00
Spread: 33.00 (2.716%)
Market Cap: £847.40m
CVSG Live PriceLast checked at - London Stock Exchange

Intraday CVS Group Share Chart

Completion of Crematorium Operations Disposal

19 May 2025 07:00

RNS Number : 0933J
CVS Group plc
19 May 2025
 

19 May 2025

 

CVS Group plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

 

Completion of Crematorium Operations Disposal

 

 

CVS, the UK listed veterinary group and a leading provider of veterinary services, announces the completion of the disposal of its Crematoria operations ("Crematoria") to Anima Care UK Limited, part of the Funecap Group, which was previously announced on 24 April 2025. Cash consideration is £42.4m which represents a 10x multiple of adjusted EBITDA1.

 

For accounting purposes, the Crematoria operations are to be treated as discontinued in the FY2025 results, adjusting forecasted revenues from continuing operations by approximately £12.3m, forecasted adjusted EBITDA1 by approximately £4.3m and forecasted profit before tax by approximately £3.3m. It is expected that CVS will report a one-off profit on the disposal in the region of £32.0m as an exceptional gain in its FY2025 accounts.

 

Australia update: Acquisitions

The Group has completed the previously announced acquisition of VPP Group PTY Ltd t/a Veterinary Practice Partners on 24 April 2025, comprising six practice sites in Victoria. The Group has made six acquisitions comprising 14 practice sites in the financial year to date, for aggregate initial considerations of A$55.8m/£28.2m.

 

The Group now has 28 practices in Australia comprising 42 practice sites. The Group has a strong pipeline of future acquisition opportunities with contracts exchanged for a further acquisition (comprising one practice site) and a healthy deal pipeline. 

 

 

Notes:

1. Adjusted EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation) is profit before tax adjusted for interest (net finance expense), depreciation, amortisation, costs relating to business combinations, and exceptional items.

 

CVS Group plc via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

 

Peel Hunt LLP (Nominated Adviser & Joint Broker) +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark /

 

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Michael Burke / James Thompson / Milo Bonser

 

Camarco (Financial PR)

Ginny Pulbrook +44 (0)7961 315 138

Letaba Rimmell

Tilly Butcher

 

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group now operates c.460 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

 

The Group employs c.9,000 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISEAKSKFAPSEFA
Date   Source Headline
15th Jun 20267:00 amRNSTransaction in Own Shares
12th Jun 202611:08 amRNSHolding(s) in Company
12th Jun 202610:06 amRNSHolding(s) in Company
8th Jun 20262:43 pmRNSStandard form for notification of major holdings
8th Jun 20262:41 pmRNSUpdated: Transaction in Own Shares
8th Jun 20267:00 amRNSTransaction in Own Shares
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20267:00 amRNSTotal Voting Rights
28th May 20267:00 amRNSPDMR Dealing
26th May 20267:02 amRNSChanges to NEDs' Responsibilities
26th May 20267:01 amRNSCommencement of Share Buyback Programme
26th May 20267:00 amRNSRefinancing, Launch of SBB and Acquisition
8th May 20263:55 pmRNSStandard form for notification of major holdings
30th Apr 20267:00 amRNSTotal Voting Rights
21st Apr 202612:46 pmRNSNon-Executive Director Appointment
20th Apr 20264:45 pmRNSStandard form for notification of major holdings
31st Mar 20267:00 amRNSTotal Voting Rights
30th Mar 20267:00 amRNSCEO retirement
25th Mar 20267:00 amRNSNon-Executive Director Changes
24th Mar 20267:13 amRNSResponse to CMA Summary Final Decision Report
27th Feb 20267:00 amRNSTotal Voting Rights
26th Feb 20267:00 amRNSInterim Results
30th Jan 20267:00 amRNSTotal Voting Rights
29th Jan 20262:02 pmRNSStandard form for notification of major holdings
29th Jan 20268:00 amRNSReadmission - CVS Group Plc
29th Jan 20267:00 amRNSAdmission to Trading on the Main Market of the LSE
28th Jan 20267:08 amRNSResponse to DEFRA consultation
27th Jan 20262:31 pmRNSStandard form for notification of major holdings
23rd Jan 202612:19 pmRNSPublication of Prospectus and Trading Update
23rd Jan 20267:00 amRNSProgramme completion and transaction in own shares
22nd Jan 20267:00 amRNSTransaction in Own Shares
21st Jan 20267:00 amRNSTransaction in Own Shares
20th Jan 20267:00 amRNSTransaction in Own Shares
19th Jan 20269:51 amRNSStandard form for notification of major holdings
19th Jan 20267:00 amRNSTransaction in Own Shares
16th Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
14th Jan 20264:24 pmRNSStandard form for notification of major holdings
14th Jan 20267:00 amRNSTransaction in Own Shares
13th Jan 20267:00 amRNSTransaction in Own Shares
12th Jan 20267:00 amRNSBlock Listing Interim Review
12th Jan 20267:00 amRNSTransaction in Own Shares
9th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20264:31 pmRNSStandard form for notification of major holdings
8th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
6th Jan 20269:34 amRNSDirector/PDMR Shareholding
6th Jan 20267:00 amRNSTransaction in Own Shares
5th Jan 20267:00 amRNSTransaction in Own Shares
2nd Jan 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.